Want to see TSE:LABS full AI Analyst Report?
LABS Stock Chart & Stats
C$0.08
<C$0.01(7.69%)
At close: 4:00 PM EST
C$0.08
<C$0.01(7.69%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.10
Previous CloseN/A
Volume690.59K
Average Volume (3M)466.64K
Market Cap
C$31.86M
Enterprise ValueC$19.89
Total Cash (Recent Filing)C$9.87M
Total Debt (Recent Filing)C$18.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 17, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding424,864,260
10 Day Avg. Volume458,518
30 Day Avg. Volume466,636
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)C$38.98M
Bulls Say, Bears Say
Bulls Say
Balance Sheet & LiquidityVery low leverage and nearly $10M cash provide durable financial flexibility. This reduces refinancing and interest-rate risk, funds ongoing restructuring savings and selective M&A or regulatory commercialization steps, and lengthens runway while profitability is improved.
High Gross Margin And Cost DisciplineSustained 30%+ gross margins combined with meaningful operating-cost cuts support structural margin improvement. That allows the firm to absorb volume softness, convert to positive adjusted EBITDA and focus on higher‑margin product mix, improving long-term cash generation prospects.
Regulatory Credentials & International TractionPharma‑grade manufacturing credentials and EU/Canada regulatory approvals create durable barriers and optionality for API and clinical supply. Combined with expanding orders in France, Brazil, Germany and NZ, this diversifies revenues into regulated, higher‑value channels.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow indicates the business still consumes cash despite margin gains. Continued cash burn can constrain reinvestment and force external financing if profitability and working capital trends don't improve over the next several quarters.
Revenue Decline & Channel ContractionTop‑line weakness and a contracting adult‑use/wellness channel limit leverage from fixed cost cuts. International rollout timing and reimbursement changes (Veterans' cut) can delay volume recovery, making margin gains harder to sustain absent durable revenue growth.
Ongoing Losses And Negative ReturnsDespite improved trends, sustained net losses and deeply negative ROE show the capital base is not yet earning a return. This undermines internal funding capacity and could erode equity value if operating profitability is not achieved persistently.
MediPharm Labs News
LABS FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was C$0.06 and its highest was C$0.10 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is C$31.86M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Aug 17, 2026 which is in 25 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on May 13, 2026. The company reported C$0 earnings per share for the quarter, beating the consensus estimate of -C$0.003 by C$0.003.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 424,864,260 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of C$0 in its last earnings report, beating expectations of -C$0.003. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in TSE:LABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across Canada, Australia, Germany, and other international territories. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations. Furthermore, MediPharm Labs provides auxiliary services including GMP-certified flower procurement, specialized packaging, and comprehensive logistics. This enterprise was established in 2015 and has its corporate headquarters situated in Barrie, Canada.